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Repeated measurements of smoking, cervical human papillomavirus (HPV) status and sex-
ual behaviour were used to measure the risk of high-grade cervical intraepithelial neopla-
sia (CIN) in relation to changes in smoking and cervical HPV status, and to explore the
impact of smoking on the acquisition and duration of incident cervical HPV infection.
Included in this longitudinal analysis are 1485 women aged 15–19 years: 1075 were HPV-
negative and cytologically normal at recruitment; 410 were HPV-positive, cytologically
abnormal or both, at this time. Women re-attended every 6 months, when samples were
taken for cytological and virological examination. Current smoking intensity was associ-
ated with an increased risk of high-grade CIN, after controlling for cervical HPV status
(compared to non-smokers, hazards ratio (HR) for 10 or more cigarettes per day = 2.21,
95% confidence interval (CI) 1.19–4.12, p-trend = 0.008). In women who were HPV-negative
and cytologically normal at recruitment, current smoking was not significantly associated
with the risk of acquiring a cervical HPV infection, after controlling for life-time number of
partners and age of oldest partner (HR = 1.13, 95% CI 0.90–1.41); nor did it prolong the length
of time during which HPV could be detected (HR = 1.03, 95% CI 0.78–1.34). Current smoking
intensity is an independent risk factor for high-grade CIN in young women, after control-
ling for cervical HPV infection.
 2009 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Cervical human papillomavirus (HPV) infection, a common
sexually transmitted disease, is considered a necessary but
not sufficient cause of cervical cancer, and attention is now
focused on identifying cofactors which modulate its progres-
sion to high-grade cervical intraepithelial neoplasia (CIN) andCancer Research UK.
8876; fax: +44 (0) 121 414
. Collins).
C BY-NC-ND license.invasive disease.1 Cigarette smoking has long been suspected
of increasing the risk of cervical neoplasia, but an association
has been difficult to prove because smoking is strongly corre-
lated with various aspects of sexual behaviour. However, a
pooled analysis of 23 case-control and longitudinal studies,
which included 13,000 cases and 23,000 controls, has shown
that, compared with women who had never smoked, current3700.
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noma in situ and cervical cancer: this risk increased with the
number of cigarettes smoked daily, and persisted when the
analyses were restricted to women who tested positive for
oncogenic HPV types.2 This analysis also showed that the risk
of cervical neoplasia increased with decreasing age of smok-
ing initiation, but surprisingly not with smoking duration.2
These observations are intriguing, but beg another question:
if early age at smoking initiation is a risk factor for cervical
neoplasia, how quickly do smoking-associated changes in
the incidence of high-grade CIN manifest themselves? This
question can only be answered by a longitudinal study. We
have addressed this question using observations made on a
cohort of young women who had recently become sexually
active and who were free of disease and HPV-negative at
study entry. We also explore, in the same study population,
the impact of smoking on the acquisition and duration of
incident cervical HPV infections.2. Materials and methods
The study design and characteristics of the study population
have been described elsewhere.3 In brief, 2011 women aged
15–19 years were recruited from a single Birmingham Brook
Advisory Centre (a family planning clinic) in Birmingham,
United Kingdom, between 1988 and 1992, and asked to return
at intervals of 6 months: follow-up ended on 31st August
1997. At recruitment a standardised interview questionnaire
was used to construct a detailed social, sexual and behav-
ioural risk factor profile, including smoking and sexual
behaviour. At each follow-up visit: sexual and smoking histo-
ries were collected or updated; and one cervical sample was
taken for cytological examination, followed by another
which was stored for subsequent virological examination.
All women with an abnormal smear were immediately re-
ferred to a colposcopy clinic for histological examination,
irrespective of the severity of that abnormality. Colposcopic
and cytological surveillance was maintained in these women
and treatment postponed until there was histological evi-
dence of high-grade CIN (CIN2 or CIN3), at which point wo-
men left the study.
After all clinical follow-up had ended, cervical cytology
samples were tested for the presence of HPV DNA using a
general primer (GP5+/GP6+) mediated polymerase chain reac-
tion (PCR), and further PCR tests were done with type-specific
primers on samples that were HPV-positive after ethidium
bromide staining.3 The study was approved by the appropri-
ate research ethics committee, and informed oral consent
was obtained from all women.
2.1. Statistical analysis
For this report, the study population is restricted to the subset
of all 1485 women who had further follow-up after recruit-
ment. For the analysis of the incidence of HPV infection, its
duration, and its association with smoking, the study popula-
tion was further restricted to an incident cohort, comprising
1075 women who were HPV-negative and cytologically nor-
mal at study entry, and who had further follow-up.Observations on cervical HPV status and high-grade CIN
are interval censored; their time of onset is known only to
lie in the interval between the date of the visit at which they
were first detected and the date of the immediately preceding
visit; similarly for the clearance of HPV infection. Analyses
were undertaken using a semi-parametric method for model-
ling interval-censored time-to-event data with time-depen-
dent covariates, as a generalised linear model.4 Each subject
contributed a sequence of binary variables indicating if the
event had, or had not, occurred during each interval of obser-
vation. The likelihood function from these binary data is
equivalent to that from the interval-censored data. The meth-
od is based on a proportional hazards model in which covar-
iates are incorporated parametrically, with the logarithm of
the baseline hazard function approximated by a smooth func-
tion of the observation interval midpoints; it allows for an
arbitrary observation scheme, with subjects seen at irregular
intervals and on a varying number of occasions, as occurred
in this study. Time-to-event was measured from study entry
to first detection in incidence analyses, and from the first
detection of either any HPV or the relevant HPV type, to clear-
ance, in analyses of duration; a woman was considered to
have ‘cleared’ her infection when she was first tested negative
for HPV, or for the relevant HPV type in type-specific analyses.
End of follow-up was the earliest of: date of diagnosis of high-
grade CIN, date of treatment, or date of last visit.
Time-varying covariates were assigned their current val-
ues at each study visit. Cervical HPV status was controlled
by constructing three separate time-dependent binary vari-
ables which measured whether a woman had ever been ex-
posed to HPV16, HPV18 or other HPV types; HPV16 and
HPV18, the two most common high-risk types, were detected
in sufficient numbers to make this analysis feasible. Current
cigarette smoking status was categorised as never-smoker,
ex-smoker and smoker; a ‘never-smoker’ was a woman who
was a non-smoker prior to study entry, and who did not
smoke at any time during follow-up; a woman was catego-
rised as an ex-smoker immediately after stopping smoking.
Smoking intensity was recorded as a categorical variable,
with categories 0 cigarettes smoked per day, 1–9, 10–19, 20–
29, 30–39, and 40 or more. Cumulative smoking exposure
was measured using pack-years, estimated as the midpoint
of each smoking quantity category (with the final category
set to 45), multiplied by the length of the interval during
which this quantity applied, and accumulated over the life-
time of the woman. For current smokers, the current smoking
episode was considered to have begun at the midpoint be-
tween the most recent date at which a woman reported hav-
ing started to smoke and the date of the preceding visit. When
testing the statistical significance of linear trends, an indica-
tor variable for ever having smoked, or current smoking sta-
tus, as appropriate, was also included: this is equivalent to
restricting the analysis to ever, or current, smokers, respec-
tively.5 Sexual behaviour variables available for the analysis
were age at first sexual intercourse, age of oldest sexual part-
ner, and life-time number of sexual partners, all treated as
continuous variables; only those variables which were signif-
icant in multivariate analyses including smoking were re-
tained in the final model. Tests of statistical significance
were conducted at the 5% two-sided significance level using
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constructed as appropriate.
3. Results
For the 1075 women included in the incident cohort, and the
410 in the prevalent cohort who had further follow-up after
recruitment, the median age at first sexual intercourse was
16 (range 0–19, i.e. some women were virgins at study entry)
and the median number of sexual partners at study entry
was two (range 0–21); 94% of women described themselves
as Caucasian. During follow-up, 717 women changed partner
at least once (range 0–17); 433 (29.2%) women had a partner
age 25 years or older before the end of follow-up. Six hundred
and ninety-nine women were never-smokers and 58 quit
prior to study entry; 540 women were smokers at study entry
and 188 first started or recommenced smoking after this time;
599 were still smokers at the end of follow-up.
3.1. Smoking and the risk of high-grade CIN
The risk of high-grade CIN was first investigated in the
incident cohort of 1075 women who were HPV-negative and
cytologically normal at study entry, and who had further
follow-up. Twenty-eight women in this incident cohort pro-Table 1 – The association between smoking and the incidence of
cervical HPV status (n = 1075, 28 events).
Incident cohort (n = 1075, 28 events)
Crude HR (95% CI) Adjusted HR (95%
Have you ever been a cigarette smoker?
No 1.00 (Reference) 1.00 (Reference
Yes 1.27 (0.60–2.69) 1.06 (0.50–2.28)
p = 0.54 p = 0.61
Pack-yearsb
Never-smoker 1.00 (Reference) 1.00 (Reference
(0, 1) 0.71 (0.20–2.52) 0.49 (0.14–1.77)
[1, 2) 1.55 (0.54–4.44) 1.66 (0.57–4.80)
[2, 3) 1.37 (0.37–5.02) 1.18 (0.31–4.42)
[3, +) 1.79 (0.54–5.97) 1.76 (0.52–5.91)
p-trend = 0.54 p-trend = 0.28
Current smoking status
Non-smoker 1.00 (Reference) 1.00 (Reference
Smoker 2.21 (1.04–4.68) 2.13 (1.00–4.52)
p = 0.04 p = 0.05
Duration of current smoking episodeb
Non-smoker 1.00 (Reference) 1.00 (Reference
(0, 24) 2.07 (0.66–6.45) 1.96 (0.63–6.12)
[24, 48) 2.91 (1.02–8.35) 2.72 (0.95–7.80)
[48, +) 1.94 (0.75–5.00) 1.91 (0.74–4.96)
p-trend = 0.30 p-trend = 0.37
Current smoking intensity
Non-smoker 1.00 (Reference) 1.00 (Reference
1–9 per day 1.59 (0.60–4.26) 1.68 (0.62–4.51)
10+ 2.87 (1.24–6.66) 2.54 (1.09–5.92)
p-trend = 0.002 p-trend = 0.005
HPV = human papillomavirus; CIN = cervical intraepithelial neoplasia; HR
a Adjusted for exposure to HPV16, HPV18 and other HPV types.
b [a, b) denotes the interval Pa to <b.gressed to high-grade CIN. We have previously reported that
the hazards ratio of high-grade CIN after exposure to HPV16
was 8.5 (3.7–19.2) and that after exposure to HPV18 was 3.3
(95% CI 1.4–8.1).3 Twenty-three women with high-grade CIN
tested positive for HPV DNA during follow-up: 12 were current
smokers at diagnosis, as were four of five who repeatedly
tested negative for HPV. In these analyses, because no events
occurred in current ex-smokers, women were categorised as
smokers or non-smokers, with non-smokers having a smok-
ing intensity of zero. In a univariate analysis, the risk of
high-grade CIN in current smokers was twice that of current
non-smokers; and increased significantly with smoking
intensity (Table 1). In a multivariate analysis, controlling for
past or current exposure to HPV16 or HPV18 or other HPV
types, these hazards ratios decreased slightly, but remained
significant. No association was found with the other smoking
variables. The study population for this analysis was then ex-
panded to include a further 410 women who were cytologi-
cally abnormal, HPV-positive, or both, at study entry, and
who had further follow-up (the prevalent cohort): 28 pro-
gressed to high-grade CIN. When these women were included
in the analysis, estimates of hazards ratios associated with
smoking were not substantially changed (Table 1). When this
analysis was repeated in the incident cohort with a diagnosis
of CIN2 as outcome, censoring at the first detection of CIN3,high-grade cervical intraepithelial neoplasia, controlling for
All women (n = 1485, 56 events)
CI)a Crude HR (95% CI) Adjusted HR (95% CI)a
) 1.00 (Reference) 1.00 (Reference)
1.50 (0.87–2.59) 1.33 (0.77–2.30)
p = 0.13 p = 0.29
) 1.00 (Reference) 1.00 (Reference)
1.09 (0.48–2.47) 0.94 (0.41–2.14)
1.83 (0.90–3.74) 1.56 (0.76–3.19)
2.03 (0.89–4.64) 1.79 (0.78–4.07)
1.43 (0.56–3.64) 1.40 (0.55–3.55)
p-trend = 0.31 p-trend = 0.12
) 1.00 (Reference) 1.00 (Reference)
2.19 (1.29–3.74) 2.06 (1.20–3.52)
p = 0.003 p = 0.007
) 1.00 (Reference) 1.00 (Reference)
2.29 (1.02–5.14) 2.20 (0.98–4.94)
2.89 (1.36–6.12) 2.62 (1.23–5.57)
1.85 (0.96–3.58) 1.75 (0.91–3.38)
p-trend = 0.48 p-trend = 0.54
) 1.00 (Reference) 1.00 (Reference)
2.04 (1.06–3.92) 1.90 (0.99–3.66)
2.35 (1.27–4.37) 2.21 (1.19–4.12)
p-trend = 0.01 p-trend = 0.008
= hazards ratio; CI = confidence interval.
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were only modestly attenuated.
3.2. Smoking and the acquisition of cervical HPV infection
We next investigated whether smoking increased the risk of
acquiring a cervical HPV infection. This analysis was re-
stricted to 1075 women who were HPV-negative and cytolog-
ically normal at study entry, and who had further follow-up.
The cumulative incidence at 3 years of a cervical infection
with HPV of any type, type 16 and type 18, in these women,
was 43.8% (95% CI 40.1–47.5), 10.5% (8.3–12.7) and 6.6% (4.8–
8.4), respectively, as reported previously.3 Four hundred and
seven women first acquired a HPV infection during follow-
up: 192 before starting to smoke; 198 afterwards; and 17 first
reported starting to smoke at the same visit that HPV was first
detected. One hundred and ten women were infected with
HPV16, and 64 with HPV18. In univariate analyses, there
was an increased risk of acquiring HPV associated with cur-
rent smoking status and with a history of ever having
smoked. In multivariate analyses, however, these associa-Table 2 – The association between smoking and the incidence o
events), HPV16 infection (n = 1075, 110 events) and of HPV18 in
Incidence of any HPV
Crude HR (95% CI) Adjusted HR (95% CI)a Crud
Have you ever been a cigarette smoker?
No 1.00 (Reference) 1.00 (Reference) 1.0
Yes 1.39 (1.14–1.69) 1.15 (0.93–1.41) 1.4
p = 0.001 p = 0.19 p =
Pack-yearsc
Never-smoker 1.00 (Reference) 1.00 (Reference) 1.0
(0, 1) 1.59 (1.25–2.01) 1.36 (1.06–1.74) 1.9
[1, 2) 1.16 (0.84–1.58) 0.99 (0.71–1.36) 0.9
[2, 3) 1.50 (1.01–2.21) 1.15 (0.77–1.71) 1.8
[3, +) 1.03 (0.56–1.90) 0.73 (0.39–1.37) 0.3
p-trend = 0.20 p-trend = 0.04 p-t
Current smoking status
Never-smoker 1.00 (Reference) 1.00 (Reference) 1.0
Ex-smoker 1.41 (1.04–1.93) 1.22 (0.89–1.68) 1.7
Smoker 1.38 (1.11–1.70) 1.13 (0.90–1.41) 1.2
p = 0.005 p = 0.37 p =
Duration of current smoking episodec
Never-smoker 1.00 (Reference) 1.00 (Reference) 1.0
Ex-smoker 1.41 (1.03–1.93) 1.22 (0.88–1.67) 1.7
(0, 24) 1.50 (1.12–2.01) 1.28 (0.95–1.73) 2.0
[24, 48) 1.34 (0.98–1.82) 1.10 (0.80–1.52) 0.6
[48, +) 1.30 (0.95–1.78) 1.00 (0.72–1.38) 1.1
p-trend = 0.39 p-trend = 0.15 p-t
Current smoking intensity
Never-smoker 1.00 (Reference) 1.00 (Reference) 1.0
0 1.41 (1.03–1.93) 1.22 (0.89–1.68) 1.7
1–9 per day 1.48 (1.15–1.90) 1.25 (0.97–1.62) 1.2
10+ 1.26 (0.96–1.67) 0.99 (0.74–1.32) 1.3
p-trend = 0.69 p-trend = 0.31 p-t
HPV = human papillomavirus; HR = hazards ratio; CI = confidence interva
a Adjusted for life-time number of sexual partners and age of oldest par
b Adjusted for life-time number of sexual partners.
c [a, b) denotes the interval Pa to <b.tions became non-significant after controlling for life-time
number of partners and age of oldest partner (Table 2). Similar
hazards ratios were found when the analysis was restricted to
HPV16 and HPV18 infections. There is no evidence to suggest
that the risk of acquiring a HPV infection of any type, or a
HPV16 or HPV18 infection, increases with either pack-years
of exposure to smoking, or duration of current smoking epi-
sode; however, the range of values of these variables is not
extensive in this population of young women.
3.3. Smoking and the duration of HPV infection
Finally, we investigated whether smoking prolonged the dura-
tion of a HPV infection. This analysis was restricted to the
1075 women who were HPV-negative and cytologically nor-
mal at study entry, and who had further follow-up (the inci-
dent cohort). The median duration of any HPV infection,
HPV16 and HPV18 in these women, was 13.7 (inter-quartile
range 8–25.4), 10.3 (6.8–17.3) and 7.8 (6–12.6) months, respec-
tively.3 Of 328 women with further follow-up after their first
HPV infection, 130 were smokers when HPV was first de-f cervical infection with HPV DNA of any type (n = 1075, 407
fection (n = 1075, 64 events).
Incidence of HPV16 Incidence of HPV18
e HR (95% CI) Adjusted HR (95% CI)b Crude HR (95% CI)
0 (Reference) 1.00 (Reference) 1.00 (Reference)
0 (0.96–2.05) 1.14 (0.76–1.69) 1.22 (0.74–1.99)
0.08 p = 0.53 p = 0.43
0 (Reference) 1.00 (Reference) 1.00 (Reference)
6 (1.27–3.03) 1.54 (0.99–2.40) 1.38 (0.75–2.54)
0 (0.46–1.73) 0.72 (0.37–1.41) 0.90 (0.40–2.04)
2 (0.94–3.54) 1.40 (0.71–2.74) 1.55 (0.64–3.74)
9 (0.10–1.56) 0.27 (0.07–1.10) 0.93 (0.28–3.07)
rend = 0.01 p-trend = 0.005 p-trend = 0.94
0 (Reference) 1.00 (Reference) 1.00 (Reference)
7 (1.03–3.06) 1.48 (0.85–2.58) 1.18 (0.54–2.58)
9 (0.86–1.95) 1.04 (0.67–1.59) 1.23 (0.73–2.08)
0.11 p = 0.38 p = 0.73
0 (Reference) 1.00 (Reference) 1.00 (Reference)
7 (1.03–3.05) 1.47 (0.84–2.46) 1.18 (0.54–2.58)
5 (1.23–3.41) 1.68 (1.00–2.83) 1.38 (0.65–2.92)
9 (0.31–1.52) 0.56 (0.25–1.24) 1.14 (0.50–2.61)
5 (0.64–2.06) 0.88 (0.48–1.62) 1.17 (0.57–2.41)
rend = 0.04 p-trend = 0.02 p-trend = 0.38
0 (Reference) 1.00 (Reference) 1.00 (Reference)
7 (1.03–3.06) 1.48 (0.85–2.58) 1.18 (0.54–2.58)
8 (0.77–2.10) 1.05 (0.63–1.75) 1.15 (0.60–2.22)
2 (0.79–2.20) 1.03 (0.60–1.75) 1.31 (0.68–2.52)
rend = 0.29 p-trend = 0.20 p-trend = 0.98
l.
tner.
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time; 12 of these women stopped smoking before the end of
follow-up. Two hundred and sixty-nine women cleared their
HPV infection during follow-up. Duration of any HPV infec-
tion, and of HPV16 infection, was unrelated to smoking; the
sample size (n = 55) was insufficient for meaningful analysis
of the duration of HPV18 (Table 3).
4. Discussion
We have shown that smoking is a risk factor for incident high-
grade CIN in young women soon after they become sexually
active. Current smokers were twice as likely to be diagnosed
with high-grade CIN as non-smokers, after controlling for
HPV status; this risk increased with current smoking inten-
sity, and the magnitude of the effect was consistent with that
observed in case-control and longitudinal studies performed
in older women.2 However, by making repeated measure-
ments of smoking and HPV status in women who were free
of disease and HPV-negative at study entry, we were able to
reduce the risk of misclassification of exposure status. We
were also able to avoid the residual confounding by time from
first HPV exposure which may occur in case-control studiesTable 3 – The association between smoking and the duration o
events) and of HPV16 infection (n = 90, 76 events).
Duration of HPV of
Crude HR (95%






(0, 1) 1.25 (0.91–1.71)
[1, 2) 0.92 (0.62–1.36)
[2, 3) 0.96 (0.59–1.54)







Duration of current smoking episodea
Never-smoker 1.00 (Reference
Ex-smoker 1.14 (0.78–1.66)
(0, 24) 1.18 (0.80–1.74)
[24, 48) 1.12 (0.73–1.73)





1–9 per day 1.20 (0.87–1.65)
10+ 0.86 (0.61–1.22)
p-trend = 0.12
HPV = human papillomavirus; HR = hazards ratio; CI = confidence interva
a [a, b) denotes the interval Pa to <b.when HPV status is measured at only a single point in time,
or which can occur in longitudinal studies when HPV status
is only defined at enrolment.1,2 Under-reporting of smoking
behaviour could have had an influence on the analysis of this
outcome, but would only have resulted in estimates of haz-
ards ratios closer to the null value. We found no excess risk
of high-grade CIN in former smokers, consistent with the
pooled analysis described already, which concluded that the
risk associated with past-smoking remains uncertain.2
It has been suggested that smoking could increase the risk
of cervical neoplasia by increasing the risk of acquiring a cer-
vical HPV infection. Revealing such an association requires
careful consideration of the confounding effect of sexual
behaviour, which is strongly correlated with smoking: failure
to control for this may result in spurious measures of associ-
ation.6 Although we found an increased risk of acquiring a
HPV infection associated with smoking, this was attenuated
after adjustment for age of oldest partner and life-time num-
ber of sexual partners. Under-reporting of sexual behaviour
might have explained a positive association between smoking
and the risk of acquiring a HPV infection, but not the absence
of an association. Under-reporting of smoking behaviour
could have had an influence on the analysis of this outcome,f cervical infection with HPV DNA of any type (n = 328, 269
any type Duration of HPV16
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However, our findings are consistent with most other longitu-
dinal studies of incident type-specific HPV infections.7–10
Although one such study did report an increased risk of inci-
dent HPV infection associated with current smoking, after
adjusting for the acquisition of a new sexual partner in the
preceding 12 months, it did not distinguish between cervical
and vulvovaginal infections;11 another found an increased
risk only in HIV-infected women.12 Recent cross-sectional
studies, which of course cannot distinguish between those
factors associated with the acquisition of HPV from those
associated with its persistence, continue to report inconsis-
tent findings.13–17 The most compelling of these, which in-
cluded information on the prevalence of HPV in women
recruited from 10 areas in four continents, found that among
current smokers, the risk of being HPV-positive increased sig-
nificantly with smoking intensity.15 However, a clear dose–
response relationship was seen only in women with one
life-time sexual partner and the authors suggest that, had
they been able to adjust their analysis for other aspects of
sexual behaviour, then this association might have been
attenuated. We believe that there is, as yet, insufficient evi-
dence to conclude that smoking increases the risk of acquir-
ing cervical HPV infection.
Although smoking is reported to impair the antibody re-
sponse in women infected with HPV, we found no evidence
that smoking prolonged either the duration of infection with
any HPV, or specifically that of HPV16.16,18,19 When measuring
duration, we defined the onset of infection as the first detec-
tion of HPV DNA or of type-specific HPV DNA in women who
tested negative for HPV DNA of any type at study entry; others
have defined onset of infection as the first detection of a HPV
type not present at baseline. In none of these studies how-
ever, was smoking shown to significantly increase the dura-
tion of infection.7,12,20
In contrast, inconsistent findings have been reported in
studies which measure the duration of type-specific infec-
tions already present at study entry (prevalent type-specific
infections). When the study population is defined in this
way, the time of onset of infection, and hence the duration
of infection, is unknown, and spurious measures of associa-
tion may be revealed.21–23 For example, one study found a sig-
nificant and substantial reduction in the time to clearance of
prevalent HPV16 and related infections in ever smokers com-
pared to never-smokers, but no evidence of an association in
those with incident infections.24
If smoking neither increases the risk of acquiring HPV
infection, nor prolongs the duration of infection, then other
mechanisms have to be invoked to explain its association
with cervical neoplasia. One stream of enquiry flows from re-
cent observations suggesting that exposure to certain behav-
ioural and environmental factors during critical periods of
development can result in persistent epigenetic changes
which have phenotypic consequences.25 Smoking-induced
epigenetic changes offer a possible explanation for the asso-
ciations we have revealed, given that the onset of sexual
activity in young women is followed by extensive remodelling
of cervical epithelium, a process which is accelerated by ciga-
rette smoking.26 Such changes are biologically plausible be-
cause nicotine and its derivatives are found in the cervicalmucus of smokers: in vitro studies in untransformed and
transformed cell lines show that short-term exposure to nic-
otine or cigarette smoke extract is followed by changes in the
expression of the DNA methyltransferases DNMT1, DNMT3A
and DNMT3B.27–29 Empirical evidence in support of this prop-
osition comes from the observation that aberrant methyla-
tion of the tumour suppressor gene, p16 (CDNK2A), is
strongly associated with current smoking in women with
squamous cell cervical cancers and high-grade CIN.30 How-
ever, for smoking-induced epigenetic changes to be a credible
explanation for the increased risk of cervical neoplasia ob-
served in young women, and not simply a consequence of
the disease process, it will first be necessary to demonstrate
in women who are free of disease, that smoking initiation
precedes the appearance of these changes in cervical mate-
rial. Such studies are underway.
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